ABL1 | C-abl oncogene 1, non-receptor tyrosine kinase | Cancer-related genes Disease related genes Enzymes FDA approved drug targets RAS pathway related proteins
| | | | | Expressed in all |
ADA | Adenosine deaminase | Disease related genes Enzymes FDA approved drug targets Plasma proteins
| | | | | Tissue enriched |
ADK | Adenosine kinase | Disease related genes Enzymes FDA approved drug targets
| | | | | Expressed in all |
APEX1 | APEX nuclease (multifunctional DNA repair enzyme) 1 | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins
| | | | | Expressed in all |
ATIC | 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins
| | | | | Expressed in all |
BLVRB | Biliverdin reductase B (flavin reductase (NADPH)) | Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Expressed in all |
CA4 | Carbonic anhydrase IV | Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CAT | Catalase | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins
| | | | | Expressed in all |
CES1 | Carboxylesterase 1 | Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Group enriched |
CPT1A | Carnitine palmitoyltransferase 1A (liver) | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins Predicted membrane proteins
| | | | | Expressed in all |
CPT2 | Carnitine palmitoyltransferase 2 | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins
| | | | | Expressed in all |
CYP51A1 | Cytochrome P450, family 51, subfamily A, polypeptide 1 | Enzymes FDA approved drug targets Predicted membrane proteins
| | | | | Expressed in all |
DHODH | Dihydroorotate dehydrogenase (quinone) | Disease related genes Enzymes FDA approved drug targets Mitochondrial proteins Predicted membrane proteins
| | | | | Expressed in all |
DNMT1 | DNA (cytosine-5-)-methyltransferase 1 | Disease related genes Enzymes FDA approved drug targets Plasma proteins Transcription factors
| | | | | Expressed in all |
DPEP1 | Dipeptidase 1 (renal) | Enzymes FDA approved drug targets Predicted secreted proteins
| | | | | Tissue enhanced |
EGFR | Epidermal growth factor receptor | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Tissue enhanced |
ERBB2 | V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Expressed in all |
FASN | Fatty acid synthase | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins
| | | | | Expressed in all |
FDPS | Farnesyl diphosphate synthase | Enzymes FDA approved drug targets Plasma proteins
| | | | | Expressed in all |
FGFR2 | Fibroblast growth factor receptor 2 | Cancer-related genes CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Mixed |
FLT4 | Fms-related tyrosine kinase 4 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins RAS pathway related proteins
| | | | | Mixed |
GANAB | Glucosidase, alpha; neutral AB | Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Expressed in all |
GSR | Glutathione reductase | Cancer-related genes Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins
| | | | | Expressed in all |
HDAC1 | Histone deacetylase 1 | Enzymes FDA approved drug targets Plasma proteins
| | | | | Expressed in all |
HDAC2 | Histone deacetylase 2 | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins
| | | | | Expressed in all |
HDAC3 | Histone deacetylase 3 | Enzymes FDA approved drug targets
| | | | | Expressed in all |
HDAC6 | Histone deacetylase 6 | Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins
| | | | | Expressed in all |
IDE | Insulin-degrading enzyme | Enzymes FDA approved drug targets Plasma proteins Predicted secreted proteins
| | | | | Expressed in all |
IKBKB | Inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta | Disease related genes Enzymes FDA approved drug targets Plasma proteins RAS pathway related proteins
| | | | | Expressed in all |
IMPDH1 | IMP (inosine 5'-monophosphate) dehydrogenase 1 | Disease related genes Enzymes FDA approved drug targets
| | | | | Expressed in all |
IMPDH2 | IMP (inosine 5'-monophosphate) dehydrogenase 2 | Enzymes FDA approved drug targets Plasma proteins
| | | | | Expressed in all |
INSR | Insulin receptor | CD markers Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins RAS pathway related proteins
| | | | | Expressed in all |
MAP2K1 | Mitogen-activated protein kinase kinase 1 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets RAS pathway related proteins
| | | | | Expressed in all |
MAP2K2 | Mitogen-activated protein kinase kinase 2 | Cancer-related genes Disease related genes Enzymes FDA approved drug targets RAS pathway related proteins
| | | | | Expressed in all |
MAPK1 | Mitogen-activated protein kinase 1 | Cancer-related genes Cytoskeleton related proteins Enzymes FDA approved drug targets Plasma proteins RAS pathway related proteins
| | | | | Expressed in all |
MAPK3 | Mitogen-activated protein kinase 3 | Cancer-related genes Cytoskeleton related proteins Enzymes FDA approved drug targets RAS pathway related proteins
| | | | | Expressed in all |
MET | Met proto-oncogene | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins RAS pathway related proteins
| | | | | Mixed |
METAP2 | Methionyl aminopeptidase 2 | Enzymes FDA approved drug targets Plasma proteins
| | | | | Expressed in all |
MMP10 | Matrix metallopeptidase 10 (stromelysin 2) | Cancer-related genes Enzymes FDA approved drug targets Predicted secreted proteins
| | | | | Tissue enriched |
MMP15 | Matrix metallopeptidase 15 (membrane-inserted) | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Mixed |
MTR | 5-methyltetrahydrofolate-homocysteine methyltransferase | Disease related genes Enzymes FDA approved drug targets Predicted secreted proteins
| | | | | Expressed in all |
PAH | Phenylalanine hydroxylase | Disease related genes Enzymes FDA approved drug targets
| | | | | Tissue enhanced |
PDE3A | Phosphodiesterase 3A, cGMP-inhibited | Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
PDXK | Pyridoxal (pyridoxine, vitamin B6) kinase | Enzymes FDA approved drug targets Plasma proteins
| | | | | Expressed in all |
PLA2G4A | Phospholipase A2, group IVA (cytosolic, calcium-dependent) | Disease related genes Enzymes FDA approved drug targets RAS pathway related proteins
| | | | | Mixed |
POLA1 | Polymerase (DNA directed), alpha 1, catalytic subunit | Enzymes FDA approved drug targets
| | | | | Expressed in all |
POLE | Polymerase (DNA directed), epsilon, catalytic subunit | Cancer-related genes Disease related genes Enzymes FDA approved drug targets Plasma proteins
| | | | | Expressed in all |
POLE2 | Polymerase (DNA directed), epsilon 2, accessory subunit | Enzymes FDA approved drug targets
| | | | | Mixed |
PRDX5 | Peroxiredoxin 5 | Enzymes FDA approved drug targets Mitochondrial proteins Plasma proteins
| | | | | Expressed in all |
PRKAA1 | Protein kinase, AMP-activated, alpha 1 catalytic subunit | Enzymes FDA approved drug targets
| | | | | Expressed in all |